| Trial ID: | L1186 |
| Source ID: | NCT02112630
|
| Associated Drug: |
P-Ifn Alfa 2a
|
| Title: |
Boceprevir in End Stage Renal Disease (ESRD)
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hepatitis C Infection|End Stage Renal Disease
|
| Interventions: |
DRUG: P-IFN alfa 2a|DRUG: P-IFN alfa 2b|DRUG: Ribavirin|DRUG: Boceprevir
|
| Outcome Measures: |
Primary: Proportion of patients who achieve sustained virologic response, Primary efficacy is the proportion of patients who achieve sustained virologic response at week 12 after discontinuation of all therapy (SVR12)., Up to 12 weeks after discontinuation of all therapy |
|
| Sponsor/Collaborators: |
Sponsor: Columbia University | Collaborators: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2013-05
|
| Completion Date: |
2015-02
|
| Results First Posted: |
|
| Last Update Posted: |
2015-09-23
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02112630
|
